Table of Contents

Living with HIV often means taking medication daily to keep the virus under control. Dovato is one of the most commonly prescribed options because it combines two active ingredients into a single pill, making treatment easier to follow. Like all medicines, however, it can cause side effects. Some are mild and temporary, while others require medical attention.

This guide explains the side effects of Dovato, supported by clinical trial data, prescribing information, and research studies. It covers what to expect, how to manage symptoms, and when to contact your healthcare provider.

Key Takeaways

  • Most side effects are mild and self-limiting, with trials consistently reporting issues like headache, nausea, and fatigue that often improve as treatment continues.
  • Rare but serious problems like liver failure, pancreatitis, and lactic acidosis can occur, even in people without obvious risk factors.
  • Pre-existing conditions raise risks, especially for those with hepatitis, kidney impairment, or metabolic disorders, which can make complications more likely.
  • Immune recovery can trigger new issues, with IRIS sometimes unmasking hidden infections or autoimmune conditions once the immune system strengthens.

What is Dovato?

Dovato contains two medicines in one tablet:

    • Dolutegravir (50 mg) – an integrase strand transfer inhibitor (INSTI) that blocks the HIV enzyme needed for viral replication.
    • Lamivudine (300 mg) – a nucleoside reverse transcriptase inhibitor (NRTI) that prevents the virus from copying its genetic material.

Together, they stop HIV from multiplying in the body. Dovato is used for adults and adolescents weighing at least 25 kg, either as first-line treatment or as a switch from another HIV regimen.

Dovato side effects

The most common side effects of Dovato

Clinical trials like GEMINI, TANGO, and SALSA, along with post-marketing studies, provide the following data on common reactions:

    • headache
    • nausea
    • diarrhea
    • insomnia
    • fatigue
    • anxiety

Rates in individual trials vary, but the pattern is consistent. Most events are mild to moderate and improve on their own.

Less common but serious side effects

Though rare, serious adverse reactions need careful attention. These include:

1. Liver-related problems

If you’ve ever had hepatitis B or C, your liver may be more sensitive to treatment with Dovato. This means you could be at higher risk for new or worsening liver test results. But even people without liver disease or obvious risk factors have experienced liver problems, including liver failure, while taking Dovato.

Your doctor will likely order blood tests to keep an eye on your liver during treatment. Be sure to contact your doctor right away if you notice any of these warning signs:

    • Yellowing of your skin or the whites of your eyes (jaundice)
    • Dark, tea-colored urine
    • Pale or clay-colored stools
    • Nausea or vomiting
    • Loss of appetite
    • Pain or tenderness on the right side of your stomach

2. Pancreatitis

Lamivudine, a component of Dovato, has been linked to rare cases of pancreatitis, mostly in children. Doctors usually only prescribe Dovato in these cases when no other effective treatment options are available.

In a case report, a 45-year-old man with HIV came to the hospital with severe stomach pain after meals, along with nausea and vomiting. His tests showed high lipase (a pancreas enzyme), confirming acute pancreatitis. Other possible causes, like alcohol, gallstones, or very high triglycerides, were ruled out.

He had just been discharged a week earlier for pancreatitis, thought to be related to his HIV medication Triumeq, which contains lamivudine, dolutegravir, and abacavir.

Although doctors had told him to stop the medicine, he mistakenly kept taking it.

This led to pancreatitis happening again. Since neither dolutegravir nor abacavir is strongly linked to pancreatitis, lamivudine was considered the main trigger. After changing medications, he has remained well with no more pancreatitis episodes.

If you develop warning signs of pancreatitis, such as severe stomach pain, nausea, vomiting, or abnormal blood test results (like high amylase, lipase, or triglycerides), treatment with Dovato should be stopped right away.

3. Lactic acidosis

Lactic acidosis is a very rare but serious side effect that can happen with certain HIV medicines called NRTIs, such as lamivudine. It can even be life-threatening. Although dolutegravir is not known to cause lactic acidosis, lamivudine sometimes can, especially if it builds up in the body due to kidney problems or affects how the cells make energy.

Some factors make this complication more likely, such as being female, having obesity, or being on HIV treatment for a long time.

Warning signs to look out for include:

    • nausea or vomiting
    • stomach pain
    • unusual tiredness
    • trouble breathing
    • an enlarged or tender liver
    • muscle pain

If any of these symptoms appear, medical help should be sought right away.

The risk of lactic acidosis increases when it interacts with other drugs, like metformin and trimethoprim.

A 70-year-old man with HIV, who had recently received a kidney transplant, died from a sudden and severe condition called metabolic acidosis, or too much acid in the blood.

He was being treated with HIV medication containing dolutegravir, lamivudine, and abacavir. One month after his transplant, he developed a serious infection of the soft tissue. His kidneys were failing, and he also had sepsis, which is a severe bloodstream infection.

Lamivudine usually leaves the body through the kidneys. Because his kidneys were not working well, the drug built up in his body. He was also taking another medicine (trimethoprim) that slows the removal of lamivudine, making the problem worse.

Tests showed his lamivudine level was 50 times higher than normal. This overdose effect, combined with infection and kidney failure, likely triggered lactic acidosis (high lactic acid in the blood), which became fatal.

In another case, a 48-year-old woman from India had HIV, type 2 diabetes, hypothyroidism, and high blood pressure. She was already on tenofovir, lamivudine, and dolutegravir for HIV. When doctors added metformin to control her blood sugar, she developed lactic acidosis.

4. Immune reconstitution inflammatory syndrome (IRIS)

When starting HIV treatment with medicines like Dovato, the immune system can begin to recover. As it gets stronger, it may suddenly react to infections that were already in the body but not causing symptoms before. This reaction is called immune reconstitution inflammatory syndrome (IRS).

It can cause inflammation and may bring out illnesses such as:

    • Tuberculosis
    • PCP (a type of pneumonia)
    • CMV (a viral infection)
    • Mycobacterium avium infection

In these cases, additional tests or treatments may be needed.

Sometimes, the immune system’s recovery can also trigger autoimmune conditions, where the body attacks its own tissues. Examples include:

    • Graves’ disease (thyroid problem)
    • Polymyositis (muscle inflammation)
    • Guillain-Barré syndrome (nerve disorder)

Unlike infections, these autoimmune problems can take months to appear after starting therapy.

5. Severe allergic reactions

Some people taking Dovato have experienced hypersensitivity reactions. These are allergic-type reactions that may include rash, flu-like symptoms, and, in rare cases, problems with organs such as the liver. In large clinical studies, this happened in less than 1% of patients.

If you notice signs of a hypersensitivity reaction, stop taking Dovato right away and contact your doctor. Warning signs include:

    • a severe rash or rash with fever, tiredness, or body aches
    • blisters, peeling skin, or sores in the mouth
    • red or irritated eyes (conjunctivitis)
    • swelling of the face or lips
    • trouble breathing
    • signs of liver problems (such as yellowing of the skin or eyes)

Your doctor will likely run blood tests and start treatment if needed. Delaying medical care or continuing Dovato despite these symptoms can lead to a life-threatening reaction.

Related Articles

Other reported side effects of Dovato

In addition to the side effects seen in clinical trials, some other reactions have been reported after Dovato became available on the market.

Changes in serum creatinine

Dolutegravir can cause a small rise in serum creatinine, a blood test often used to check kidney health. This happens because the drug slows the way creatinine leaves the body through the kidney’s tubules, but it does not actually harm kidney filtering function.

The increase usually appears in the first month of treatment and then stays steady. After almost 3 years (144 weeks), the average rise was about 0.14-0.18 mg/dL, which is considered small and not harmful.

Weight gain

An unexpected excess in weight gain has recently been reported in dolutegravir-containing regimens.

In one study, researchers followed 713 adults with HIV who started dolutegravir-based treatment between 2014 and 2019. The most weight gain happened in people taking dolutegravir with tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) or DTG with tenofovir alafenamide (TAF)/FTC.

People who were new to treatment and those with low CD4 counts (<200) were more likely to gain more than 10% of their starting weight. On the other hand, people who were heavier to begin with and women had a lower risk of big weight gains.

A separate study had similar findings. Dolutegravir-based treatment led to an average weight gain of 5.3 kg (11.7 lb). The largest increase was seen in people on dolutegravir plus TAF/emtricitabine, resulting in an average of 6.7 kg (14.8 lb) over 5 years.

Hair loss

Large clinical trials of Dovato did not list alopecia (hair loss) as a typical problem. However, there have been postmarketing reports of hair loss with certain HIV medicines.

For example, some older drugs in the protease inhibitor class, especially indinavir, and the NRTI lamivudine (one of the two drugs in Dovato), have been linked to hair loss in a small number of case reports.

Most patients lost hair only on the scalp, and symptoms started on average about 2.5 months after beginning treatment.

Stopping the suspected drug was the most common way to manage the problem. About half of the patients saw at least partial regrowth. Hair usually grows back within 1 to 3 months after stopping.

If you experience unusual hair loss while taking Dovato, let your healthcare provider know. They can check for other causes, such as stress, nutritional deficiencies, thyroid problems, or family history of alopecia, before deciding if your medication may be causing it.

To sum it up

Dovato is an effective HIV treatment that combines dolutegravir and lamivudine in one pill. Most side effects, like headache, nausea, diarrhea, fatigue, and insomnia, are mild and improve with time. Serious but less common risks include liver problems, pancreatitis, lactic acidosis, IRIS, and severe allergic reactions. Postmarketing reports also note weight gain, small increases in creatinine, and rare cases of hair loss.

Dovato works well for controlling HIV, but regular monitoring is needed. Report any unusual symptoms to your doctor right away.

Frequently Asked Questions

Dovato and Biktarvy cause similar side effects, as their active ingredients belong to the same drug classes. However, a 2024 report showed that patients who switched from Dovato to Biktarvy experienced less nausea and fewer cases of abdominal discomfort. In addition, Biktarvy is linked to more weight gain in real-world use.

You should avoid using it with dofetilide, since this interaction can cause serious complications. Antacids or supplements containing magnesium, calcium, aluminum, or iron can also interfere with absorption, so they must be timed carefully. Strong enzyme inducers such as rifampin or certain seizure medications may reduce drug levels.

The side effects of Dovato, like nausea, headache, or insomnia, usually appear within the first weeks and tend to improve on their own in days to weeks. Some mild symptoms or lab abnormalities may last longer, but severe or persistent problems should be checked by a doctor.

Dovato is not typically harsh on the kidneys, but it is not advised for people whose creatinine clearance is below 30 mL/min because lamivudine cannot be adjusted in that setting. It may also interact with drugs processed by the kidneys, such as metformin, which can raise the chance of side effects.

Sleep problems are a recognized reaction to Dovato, with insomnia and anxiety reported in trials and patient experiences. These effects often improve over time but may bother some individuals enough to need medical guidance.

Stopping Dovato usually leads to HIV rebounding, with viral loads increasing within days to weeks and immune decline following. For people who also have hepatitis B, stopping the medicine can cause the infection to flare up again, sometimes severely.

Most side effects from Dovato are temporary and resolve either with continued treatment or after discontinuation. Rarely, liver injury or other serious reactions may leave lasting damage, though these cases are uncommon.

Magnesium supplements can be taken while on Dovato, but they must be spaced properly. Dovato should be taken at least two hours before or six hours after magnesium to ensure the medicine is absorbed correctly.

Sources

Lamivudine-Induced Acute Pacreatitis: A Unique Case: 174?: Official journal of the American College of Gastroenterology | ACG. (n.d.). LWW. https://journals.lww.com/ajg/fulltext/2015/10001/lamivudine_induced_acute_pacreatitis__a_unique.174.aspx

Hollinger, A., Cueni, N., Marzolini, C., Dickenmann, M., Landmann, E., Battegay, M., Martinez, A. E., Siegemund, M., & Leuppi-Taegtmeyer, A. (2021). Lactic acidosis and hyperlactatemia associated with lamivudine accumulation and sepsis in a kidney transplant recipient—a case report and review of the literature. AIDS Research and Therapy, 18(1). https://doi.org/10.1186/s12981-021-00382-8

Zaawari, A., Varma, M., Tirlangi, P. K., Harsha, M., & Avvaru, D. (2024). Metformin-dolutegravir interaction leads to metformin-associated lactic acidosis: A case report. Indian Journal of Case Reports, 10(2), 56–58. https://doi.org/10.32677/ijcr.v10i2.4371

Taramasso, L., Bonfanti, P., Ricci, E., Orofino, G., Squillace, N., Menzaghi, B., De Socio, G. V., Madeddu, G., Pellicanò, G. F., Pagnucco, L., Celesia, B. M., Calza, L., Conti, F., Martinelli, C. V., Valsecchi, L., Cascio, A., Bolla, C., Maggi, P., Vichi, F., . . . Di Biagio, A. (2020). Factors associated with weight gain in people treated with dolutegravir. Open Forum Infectious Diseases, 7(6). https://doi.org/10.1093/ofid/ofaa195

Ando, N., Nishijima, T., Mizushima, D., Inaba, Y., Kawasaki, Y., Kikuchi, Y., Oka, S., & Gatanaga, H. (2021). Long-term weight gain after initiating combination antiretroviral therapy in treatment-naïve Asian people living with human immunodeficiency virus. International Journal of Infectious Diseases, 110, 21–28. https://doi.org/10.1016/j.ijid.2021.07.030

Woods, E. A., & Foisy, M. M. (2014). Antiretroviral-Related alopecia in HIV-Infected patients. Annals of Pharmacotherapy, 48(9), 1187–1193. https://doi.org/10.1177/1060028014540451

Randomized, multicenter, double-blind clinical trial designed to evaluate the safety and convenience of switching from dolutegravir/lamivudine to bictegravir/emtricitabine/tenofovir alafenamide in people with HIV, good virologic control and neuropsychiatric comorbidities: Week 24 results from the GESIDA 11920 – MIND Study. (n.d.). https://www.natap.org/2024/Glasgow/GLASGOW_41.htm